Equities

Medico Remedies Ltd

MEDICO:NSI

Medico Remedies Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)45.55
  • Today's Change-1.05 / -2.25%
  • Shares traded90.62k
  • 1 Year change-45.12%
  • Beta--
Data delayed at least 15 minutes, as of May 03 2024 10:59 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Medico Remedies Limited is an India-based pharmaceutical formulation manufacturing company. The Company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. It has manufacturing and marketing capabilities in formulation with focus on anti-infective, Beta-Lactums, cephalosporins, antimalarial, antiretroviral, anti-ulcer drugs and antacids, vitamins, haematinics and other supplements. In addition, the Company also manufactures other drugs, such as non-steroidal anti-inflammatory drugs (NSAIDS), antihistaminic, anti-diabetics, cardiovascular drugs, diuretics, anti-epileptics, combination drug kits, syrups and cream, and gel for various therapeutic segments. Its products include Doxycycline Capsules, Zenof-400 (Ofloxacin Tablets 400mg), Azithromycin Tablets, Aciclovir Tablets, Cipta Tablets, Cotrimoxazole Tablets, Tos Syrup, Paediatric Co-Trimozole Oral, Med Reactin (Cyproheptadine), and Medivit Syrup, among others.

  • Revenue in INR (TTM)1.32bn
  • Net income in INR69.58m
  • Incorporated1994
  • Employees--
  • Location
    Medico Remedies Ltd1105/1106, 11Th Floor, Hubtown Solaris,Andheri (East), N.S.Phadke MargTHANE 401404IndiaIND
  • Phone+91 8 046047706
  • Fax+91 2 226281059
  • Websitehttps://www.medicoremediesindia.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Brooks Laboratories Ltd744.61m-142.85m2.73bn296.00------3.67-5.65-5.6529.38--------2,515,585.00---12.10---19.5330.0226.63-19.18-28.01--0.0672-----30.692.12-85.13---39.43--
Take Solutions Ltd850.73m-113.89m3.31bn211.00------3.90-0.7833-4.445.90--------4,031,915.00---4.65---7.2555.3871.04-13.49-7.07--1.07-----71.03-34.6643.41---44.31--
Par Drugs and Chemicals Ltd973.13m142.29m3.38bn105.0023.77--19.193.4811.5611.5679.09--------9,267,876.00--11.67--14.6963.6543.3014.6211.82--210.51----27.5417.7123.0249.9464.23--
Medico Remedies Ltd1.32bn69.58m3.78bn--54.71--38.472.870.83260.832615.75------------4.76--10.0024.1524.405.293.14--11.07----16.0418.1448.0942.7852.68--
Lyka Labs Ltd1.06bn-35.60m4.24bn713.00----43.074.01-1.23-1.2333.69-------------5.48---9.3161.3759.75-3.34-10.63--0.5422-----52.058.95-133.88--17.78--
Venus Remedies Ltd.5.62bn290.26m4.26bn998.0014.68--7.370.75921.7321.73420.31--------5,630,556.00--2.84--3.8442.7639.685.173.83--559.36-----7.218.33-34.77---10.05--
Data as of May 03 2024. Currency figures normalised to Medico Remedies Ltd's reporting currency: Indian Rupee INR
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.